Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

Thomas G. Martin, MD, discusses the utility of CAR T-cell therapy in late relapsed multiple myeloma.

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discusses recent key advances in multiple myeloma.

Thomas G. Martin, MD, discusses the safety profile of bispecific T-cell engagers in multiple myeloma.

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Thomas G. Martin, MD, discusses the utility of aggressive frontline treatment in multiple myeloma.

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Thomas G. Martin, MD, discusses the safety profile of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discusses biomarker-driven treatment options in multiple myeloma and currently available regimens.

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.